

# ***Deep Vein Thrombosis in Focus: Resource Guide***

## **VTE and Cancer: A Focus on Prevention in the Oncology Patient**

---

Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol.* 2009;10(10):943-949.

Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? *J Thromb Haemost.* 2007;5(8):1610-1616.

Ansell JE. Prophylaxis and treatment of venous thromboembolism in cancer patients: a review. *Am J Clin Oncol.* 2009;32(4 Suppl):S8-S12.

Colorado Foundation for Medical Care. Surgical Care Improvement Project (SCIP). [http://www.cfmc.org/hospital/hospital\\_scip.htm](http://www.cfmc.org/hospital/hospital_scip.htm). Accessed November 12, 2009.

Dentali F, Douketis JD, Gianni M, Lim W, Gowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med.* 2007;146:278-288.

Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. *J Clin Oncol.* 2009;27(29):4874-4880.

Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):381S-453S.

Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis. *Am J Cardiol.* 2004;93(2):259-262.

Kakkar AK. Prevention of venous thromboembolism in the cancer surgical patient. *J Clin Oncol.* 2009;27(29):4881-4884.

Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thromboembolism in cancer patients; insights from the FRONTLINE survey. *The Oncologist.* 2003;8:381-388.

Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. *J Clin Oncol.* 2009;27(29):4919-4926.

Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. *J Clin Oncol.* 2009;27(29):4902-4911.

Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. *Circulation*. 2003;107:117-121.

Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. *Medicine (Baltimore)*. 1999;78(5):285-291.

Lopez JA, Kearon C, Lee AYY. Deep venous thrombosis. *Hematology Am Soc Hematol Educ Program*. 2004:439-456.

Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. *Thromb Haemost*. 2007;98(3):656-661.

Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. *J Clin Oncol*. 2009;27(29):4858-4864.

Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. *Am J Med*. 2006;119(1):60-68.

Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. *Lancet*. 2009;373(9663):567-574.